A Deep Dive into the SGN-70 This SGN-70 antibody represents a promising strategy in oncology, specifically targeting CD22 expressed on blood cancers. Developed by Seattle Genetics, the agent functions as an ADCC https://phoenixlvva594088.pointblog.net/text-92685056